Skip header and navigation

1 records – page 1 of 1.

Prostate cancer prevention

https://libcat.nshealth.ca/en/permalink/provcat33417
Jack Cuzick, Mangesh A. Thorat, editors. --Heidelberg: Springer , c2014.
Available Online
View e-Book
Location
Online
Prostate cancer is by far the most common cancer in men and the second leading cause of death due to cancer. It comprises a mixed group of tumours displaying varying clinical behaviour: while some have a very aggressive course, others are rather indolent. Prevention of prostate cancer and discrimination between aggressive and indolent forms are important clinical goals, and the acquisition of significant new evidence on means of achieving these aims makes this book particularly timely. A wide r…
Available Online
View e-Book
Other Authors
Cuzick, J
Thorat, Mangesh A
Responsibility
Jack Cuzick, Mangesh A. Thorat, editors
Place of Publication
Heidelberg
Publisher
Springer
Date of Publication
c2014
Physical Description
1 online resource (viii, 169 pages)
Series Vol.
v. 202
Series Title
Recent results in cancer research
ISBN
9783642451959 (electronic bk.)
9783642451942
Subjects (MeSH)
Prostatic Neoplasms - prevention & control
Anticarcinogenic Agents
Chemoprevention
Early Detection of Cancer
Risk Factors
Subjects (LCSH)
Prostate - Cancer - Prevention
Prostatic Neoplasms - prevention & control
Risk Assessment
Biological Markers
Life Style
Risk Factors
Diet
Chemoprevention
Oncology
Abstract
Prostate cancer is by far the most common cancer in men and the second leading cause of death due to cancer. It comprises a mixed group of tumours displaying varying clinical behaviour: while some have a very aggressive course, others are rather indolent. Prevention of prostate cancer and discrimination between aggressive and indolent forms are important clinical goals, and the acquisition of significant new evidence on means of achieving these aims makes this book particularly timely. A wide range of topics are covered by leading authorities in the field. The biology and natural history of prostate cancer are reviewed, and the role of lifestyle and dietary factors, assessed. Detailed attention is paid to risk prediction biomarkers and to the role of novel high-throughput nucleic acid-based technologies in improving risk prediction and thereby allowing tailored approaches to cancer prevention. Potential means of chemoprevention of prostate cancer are also reviewed in depth, covering the very positive new data on the impact of aspirin as well as evidence regarding 5-reductase inhibitors, DFMO, and lycopene. Guidance is provided on the differentiation of aggressive from indolent disease, and the policy and research implications of recent findings are examined. This book will be of interest to both clinicians and researchers.
Contents
The biology and natural history of prostate cancer: a short introduction -- Germline genetic variants associated with prostate cancer and potential relevance to clinical practice -- Lifestyle and dietary factors in prostate cancer prevention -- Nutrition, hormones and prostate cancer risk: results from the European prospective investigation into cancer and nutrition -- Screening for prostate cancer: current status of ERSPC and screening-related issues -- Update of the prostate, lung, colorectal, and ovarian cancer screening trial -- ERSPC, PLCO studies and critique of Cochrane review 2013 -- Screening for prostate cancer: reflecting on the quality of evidence from the ERSPC and PLCO studies -- Phase III prostate cancer chemoprevention trials -- Risk adapted chemoprevention for prostate cancer: an option? -- Aspirin and prostate cancer prevention -- Chemoprevention of prostate cancer by isoflavonoids -- Lycopene for the prevention and treatment of prostate disease -- Chemoprevention of prostate cancer with the polyamine -- Synthesis inhibitor difluoromethylornithine -- Prostate cancer prevention: agent development strategies -- Prognostic value of a cell cycle progression score for men with prostate cancer -- Distinguishing indolent from aggressive prostate cancer -- Management of low risk and low PSA prostate cancer: long term results from the prostate cancer intervention versus observation trial.
Format
e-Book
Location
Online
Less detail